James B. Pekarek Sells 14,668 Shares of Agiliti, Inc. (NYSE:AGTI) Stock

Agiliti, Inc. (NYSE:AGTI – Get Rating) CFO James B. Pekarek sold 14,668 shares of the company’s stock in a transaction that occurred on Monday, March 13th. The shares were sold at an average price of $15.03, for a total value of $220,460.04. Following the completion of the transaction, the chief financial officer now directly owns 249,071 shares of the company’s stock, valued at $3,743,537.13. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Agiliti Price Performance

Shares of NYSE AGTI opened at $14.92 on Wednesday. The stock has a fifty day simple moving average of $17.72 and a two-hundred day simple moving average of $16.95. Agiliti, Inc. has a 1-year low of $14.15 and a 1-year high of $23.25. The firm has a market cap of $2.00 billion, a price-to-earnings ratio of 71.05, a price-to-earnings-growth ratio of 16.39 and a beta of 1.40. The company has a current ratio of 1.60, a quick ratio of 1.25 and a debt-to-equity ratio of 1.14.

Hedge Funds Weigh In On Agiliti

Several institutional investors and hedge funds have recently bought and sold shares of the company. Wells Fargo & Company MN boosted its holdings in shares of Agiliti by 180.8% in the fourth quarter. Wells Fargo & Company MN now owns 1,536 shares of the company’s stock worth $25,000 after acquiring an additional 989 shares during the period. Macquarie Group Ltd. bought a new position in shares of Agiliti in the second quarter worth $28,000. Group One Trading L.P. bought a new position in shares of Agiliti in the fourth quarter worth $31,000. Clear Street Markets LLC bought a new position in shares of Agiliti in the fourth quarter worth $40,000. Finally, Dark Forest Capital Management LP bought a new position in shares of Agiliti in the second quarter worth $99,000.

Analysts Set New Price Targets

Several research firms have recently issued reports on AGTI. Bank of America lowered Agiliti from a “buy” rating to a “neutral” rating and set a $19.00 target price for the company. in a report on Friday, December 16th. Morgan Stanley lowered Agiliti from an “overweight” rating to an “equal weight” rating and set a $18.00 target price for the company. in a report on Friday, January 6th. Raymond James reduced their target price on Agiliti from $22.00 to $20.00 and set an “outperform” rating for the company in a report on Tuesday, November 15th. UBS Group reduced their target price on Agiliti to $19.00 in a report on Wednesday, November 16th. Finally, Citigroup reduced their price objective on Agiliti from $21.00 to $20.00 and set a “buy” rating for the company in a report on Wednesday, March 8th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, Agiliti has an average rating of “Moderate Buy” and an average price target of $20.88.

About Agiliti

(Get Rating)

Agiliti, Inc provides end-to-end healthcare technology management and service solutions to the United States healthcare industry. It also offers comprehensive medical equipment management and service solutions to reduce capital and operating expenses, increase medical equipment and staff productivity and support improved patient safety and outcomes.